MDT-AP-2153
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 81.36
- os_event
- false
- age_years
- 1.56
- new_clusters
- S3
- umap1_2d
- -0.492012019
- umap2_2d
- -7.161898022
- umap1_3d
- -2.498743506
- umap2_3d
- -2.592963981
- umap3_3d
- 5.2676236
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- COAGULATION+0.310
- PANCREAS_BETA_CELLS+0.310
- KRAS_SIGNALING_DN+0.270
- APICAL_SURFACE+0.260
- MYOGENESIS+0.250
- HEDGEHOG_SIGNALING+0.240
- ALLOGRAFT_REJECTION+0.210
- ANGIOGENESIS+0.200
- P53_PATHWAY+0.200
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- ANDROGEN_RESPONSE-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
- TGF_BETA_SIGNALING-0.280
- MTORC1_SIGNALING-0.220
- MITOTIC_SPINDLE-0.210
- HEME_METABOLISM-0.200
- UV_RESPONSE_DN-0.200
- IL6_JAK_STAT3_SIGNALING-0.170
- BILE_ACID_METABOLISM-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0712 | Med | Medulloblastoma | 0.823 |
| 2 | TCGA-A7-A56D-01A-11R-A27Q-07 | — | B | 0.784 |
| 3 | MDT-AP-2372 | Med | Medulloblastoma | 0.777 |
| 4 | 966a66a2-8aac-41e8-8007-88fd92d2e8e8 | — | — | 0.761 |
| 5 | TCGA-LL-A6FR-01A-12R-A31O-07 | — | E | 0.760 |
| 6 | MDT-AP-0569 | Med | Medulloblastoma | 0.750 |
| 7 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.742 |
| 8 | dc3154b7-6ae4-446a-8a80-91a86c57cefe | — | — | 0.739 |
| 9 | SAMN03290888 | — | — | 0.736 |
| 10 | TCGA-E9-A5FL-01A-11R-A27Q-07 | — | E | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |